Swedish Orphan Biovitrum ABSWOBY 67 Interest Coverage is 10.79 as of Mar. 2026, which is 14% above its 10-year median of 9.44. GuruFocus rates SWOBY with a GF Score™ of 67/100 and a GF Value™ of $17.17 (Significantly Overvalued). The stock has 7 warning signs investors should review. Among 685 Drug Manufacturers companies, Swedish Orphan Biovitrum AB ranks worse than 86.86% on this metric.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's
Operating Income
by its Interest Expense. Swedish Orphan Biovitrum AB's
Operating Income
for the
three
months ended in Mar. 2026 was $200 Mil. Swedish Orphan Biovitrum AB's Interest Expense for the
three
months ended in Mar. 2026 was $-19 Mil.
Swedish Orphan Biovitrum AB's interest coverage for the quarter that ended in Mar. 2026 was 10.79.
The higher the ratio, the stronger the company's financial strength is.
The historical rank and industry rank for Swedish Orphan Biovitrum AB's Interest Coverage or its related term are showing as below:
SWOBY'
s Interest Coverage Range Over the Past 10 Years
Min: 1.15 Med: 9.44 Max: 55.86
Current: 1.85
SWOBY's Interest Coverage is ranked worse than 86.86% of 685
companies
in the Drug Manufacturers industry
Industry Median: 12.78
vs SWOBY: 1.85
Swedish Orphan Biovitrum AB (OTCPK:SWOBY) Interest Coverage Explanation
Ben Graham requires that a company has a minimum interest coverage of 5 with the companies he invested. If the interest coverage is less than 2, the company is burdened by debt. Any business slow or recession may drag the company into a situation where it cannot pay the interest on its debt.
Interest Coverage is an important factor when GuruFocus ranks a company's overage Financial Strength .
Swedish Orphan Biovitrum AB Interest Coverage Related Terms
Swedish Orphan Biovitrum AB Interest Coverage Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note: For Interest Coverage, "No debt" indicates no long-term debt. An indication of "No Debt" does not necessarily mean that the company has no long-term debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
Swedish Orphan Biovitrum AB Interest Coverage Chart
For the Drug Manufacturers - Specialty & Generic subindustry, Swedish Orphan Biovitrum AB's Interest Coverage, along with its competitors' market caps and Interest Coverage data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Swedish Orphan Biovitrum AB Interest Coverage vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Swedish Orphan Biovitrum AB's Interest Coverage distribution charts can be found below:
* The bar in red indicates where Swedish Orphan Biovitrum AB's Interest Coverage falls into.
Swedish Orphan Biovitrum AB Interest Coverage Calculation
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Swedish Orphan Biovitrum AB (SWOBY) has a Interest Coverage of 10.79 as of Mar. 2026. Interest Coverage measures a company's capability to pay interest expenses on its debt. View historical data on Swedish Orphan Biovitrum AB and its competitors. This is 14% above median its historical median of 9.44. Over the past decade, Swedish Orphan Biovitrum AB's Interest Coverage has ranged from 1.15 to 55.86. According to the industry distribution chart, Swedish Orphan Biovitrum AB ranks #595 out of 685 companies in the Drug Manufacturers industry, placing it in the top 86.9%.
Is Swedish Orphan Biovitrum AB's Interest Coverage too high?
Swedish Orphan Biovitrum AB's current Interest Coverage of 10.79 is 14% above median its 10-year median of 9.44. Over the past 10 years, this metric has ranged from a low of 1.15 to a high of 55.86. The Drug Manufacturers industry median Interest Coverage is 12.78. Swedish Orphan Biovitrum AB's value of 10.79 is 15.6% below this industry median. Based on the distribution chart, Swedish Orphan Biovitrum AB ranks #595 out of 685 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Swedish Orphan Biovitrum AB has a GF Score™ of 67/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Swedish Orphan Biovitrum AB's Interest Coverage compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Swedish Orphan Biovitrum AB ranks #595 out of 685 companies for Interest Coverage. This places Swedish Orphan Biovitrum AB in the lower half of its industry. The industry median Interest Coverage is 12.78. Swedish Orphan Biovitrum AB's value of 10.79 is 15.6% below this benchmark. Historically, Swedish Orphan Biovitrum AB's own Interest Coverage has ranged from 1.15 to 55.86 over the past decade. While the company's 10-year median is 9.44 vs. the industry median of 12.78, Swedish Orphan Biovitrum AB has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Interest Coverage for a Drug Manufacturers company?
The median Interest Coverage among Drug Manufacturers companies is 12.78, based on 685 companies in the industry. Companies in the top quartile (top 25%) have a Interest Coverage significantly above this median, while those in the bottom quartile fall well below. However, Interest Coverage should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Swedish Orphan Biovitrum AB's current Interest Coverage of 10.79 is 15.6% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Interest Coverage mean?
A high Interest Coverage can signal that a stock is expensive relative to its fundamentals. Interest Coverage measures a company's capability to pay interest expenses on its debt. View historical data on Swedish Orphan Biovitrum AB and its competitors. For the Drug Manufacturers industry, the median Interest Coverage is 12.78 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Swedish Orphan Biovitrum AB's current Interest Coverage is 10.79, which is 14% above median its own 10-year median of 9.44. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Swedish Orphan Biovitrum AB stock overvalued right now?
Based on GuruFocus' analysis, Swedish Orphan Biovitrum AB (SWOBY) is currently considered Significantly Overvalued. The stock's GF Value™ is $17.17, compared to a current price of $23.18 — trading 35% above its estimated fair value. The current Interest Coverage is 10.79, which is 14% above median its 10-year median of 9.44 and 15.6% below the Drug Manufacturers industry median of 12.78. Swedish Orphan Biovitrum AB's overall GF Score™ is 67/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Interest Coverage calculated?
Interest Coverage is calculated from a company's financial statements. For Swedish Orphan Biovitrum AB (SWOBY), the current Interest Coverage is 10.79 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Swedish Orphan Biovitrum AB (SWOBY) Overvalued in 2026?
Based on GuruFocus' analysis, Swedish Orphan Biovitrum AB stock appears to be overvalued.
The current stock price of $23.18 is trading 35% above its estimated GF Value™ of $17.17.
GuruFocus considers Swedish Orphan Biovitrum AB to be Significantly Overvalued.
Key valuation signals for SWOBY:
Interest Coverage: 10.79 (14% above median its 10-year median of 9.44)
GF Value™: $17.17 vs. price of $23.18 (35% above fair value)
Industry Position: 15.6% below the Drug Manufacturers median (#595 of 685)
No single metric tells the full story. See the SWOBY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Swedish Orphan Biovitrum, or Sobi, focuses on rare diseases, primarily in hematology and immunology. Biovitrum started with experience in studying recombinant proteins such as hemophilia factors, and partnered with Syntonix (now part of Sanofi) in 2006 on long-acting hemophilia factor replacement programs. Biovitrum acquired Orfadin and a partnered product business with the acquisition of Swedish Orphan. Sobi launched hemophilia products Alprolix and Eloctate in Europe in 2016, and Altuvoct in 2024. Sobi has been building its immunology pipeline (rare-disease drug Gamifant, US rights to RSV antibodies Synagis and Beyfortus, gout drugs, complement drug Aspaveli) and a broader hematology pipeline (thrombocytopenia drug Doptelet, blood cancer drug Zynlonta, myelofibrosis drug Vonjo).
67GF Score
Get the complete analysis for SWOBY
Interest Coverage is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SWOBY has been successfully added to your 
